Assessment of cognition in mild cognitive impairment: A comparative study

Peter J. Snyder, Colleen E. Jackson, Ronald Carl Petersen, Ara S. Khachaturian, Jeffrey Kaye, Marilyn S. Albert, Sandra Weintraub

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer's disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective therapies. To meet these changing clinical requirements, cognitive measures or tailored batteries of tests must be validated and determined to be fit-for-use for the discrimination between cognitively healthy individuals and persons who are experiencing very subtle cognitive changes that likely signal the emergence of early mild cognitive impairment. We sought to collect and review data systematically from a wide variety of (mostly computer-administered) cognitive measures, all of which are currently marketed or distributed with the claims that these instruments are sensitive and reliable for the early identification of disease or, if untested for this purpose, are promising tools based on other variables. The survey responses for 16 measures/batteries are presented in brief in this review; full survey responses and summary tables are archived and publicly available on the Campaign to Prevent Alzheimer's Disease by 2020 Web site (http://pad2020.org). A decision tree diagram highlighting critical decision points for selecting measures to meet varying clinical trials requirements has also been provided. Ultimately, the survey questionnaire, framework, and decision guidelines provided in this review should remain as useful aids for the evaluation of any new or updated sets of instruments in the years to come.

Original languageEnglish (US)
Pages (from-to)338-355
Number of pages18
JournalAlzheimer's and Dementia
Volume7
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

Cognition
Alzheimer Disease
Decision Trees
Clinical Trials
Guidelines
Research
Cognitive Dysfunction
Surveys and Questionnaires
Therapeutics
Discrimination (Psychology)

Keywords

  • Alzheimer's disease
  • Clinical trials
  • Cognition
  • Mild cognitive impairment
  • Neuropsychological assessment

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Snyder, P. J., Jackson, C. E., Petersen, R. C., Khachaturian, A. S., Kaye, J., Albert, M. S., & Weintraub, S. (2011). Assessment of cognition in mild cognitive impairment: A comparative study. Alzheimer's and Dementia, 7(3), 338-355. https://doi.org/10.1016/j.jalz.2011.03.009

Assessment of cognition in mild cognitive impairment : A comparative study. / Snyder, Peter J.; Jackson, Colleen E.; Petersen, Ronald Carl; Khachaturian, Ara S.; Kaye, Jeffrey; Albert, Marilyn S.; Weintraub, Sandra.

In: Alzheimer's and Dementia, Vol. 7, No. 3, 05.2011, p. 338-355.

Research output: Contribution to journalArticle

Snyder, PJ, Jackson, CE, Petersen, RC, Khachaturian, AS, Kaye, J, Albert, MS & Weintraub, S 2011, 'Assessment of cognition in mild cognitive impairment: A comparative study', Alzheimer's and Dementia, vol. 7, no. 3, pp. 338-355. https://doi.org/10.1016/j.jalz.2011.03.009
Snyder, Peter J. ; Jackson, Colleen E. ; Petersen, Ronald Carl ; Khachaturian, Ara S. ; Kaye, Jeffrey ; Albert, Marilyn S. ; Weintraub, Sandra. / Assessment of cognition in mild cognitive impairment : A comparative study. In: Alzheimer's and Dementia. 2011 ; Vol. 7, No. 3. pp. 338-355.
@article{705cebd3d96a49b2af26b28ce9a06ee5,
title = "Assessment of cognition in mild cognitive impairment: A comparative study",
abstract = "The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer's disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective therapies. To meet these changing clinical requirements, cognitive measures or tailored batteries of tests must be validated and determined to be fit-for-use for the discrimination between cognitively healthy individuals and persons who are experiencing very subtle cognitive changes that likely signal the emergence of early mild cognitive impairment. We sought to collect and review data systematically from a wide variety of (mostly computer-administered) cognitive measures, all of which are currently marketed or distributed with the claims that these instruments are sensitive and reliable for the early identification of disease or, if untested for this purpose, are promising tools based on other variables. The survey responses for 16 measures/batteries are presented in brief in this review; full survey responses and summary tables are archived and publicly available on the Campaign to Prevent Alzheimer's Disease by 2020 Web site (http://pad2020.org). A decision tree diagram highlighting critical decision points for selecting measures to meet varying clinical trials requirements has also been provided. Ultimately, the survey questionnaire, framework, and decision guidelines provided in this review should remain as useful aids for the evaluation of any new or updated sets of instruments in the years to come.",
keywords = "Alzheimer's disease, Clinical trials, Cognition, Mild cognitive impairment, Neuropsychological assessment",
author = "Snyder, {Peter J.} and Jackson, {Colleen E.} and Petersen, {Ronald Carl} and Khachaturian, {Ara S.} and Jeffrey Kaye and Albert, {Marilyn S.} and Sandra Weintraub",
year = "2011",
month = "5",
doi = "10.1016/j.jalz.2011.03.009",
language = "English (US)",
volume = "7",
pages = "338--355",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Assessment of cognition in mild cognitive impairment

T2 - A comparative study

AU - Snyder, Peter J.

AU - Jackson, Colleen E.

AU - Petersen, Ronald Carl

AU - Khachaturian, Ara S.

AU - Kaye, Jeffrey

AU - Albert, Marilyn S.

AU - Weintraub, Sandra

PY - 2011/5

Y1 - 2011/5

N2 - The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer's disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective therapies. To meet these changing clinical requirements, cognitive measures or tailored batteries of tests must be validated and determined to be fit-for-use for the discrimination between cognitively healthy individuals and persons who are experiencing very subtle cognitive changes that likely signal the emergence of early mild cognitive impairment. We sought to collect and review data systematically from a wide variety of (mostly computer-administered) cognitive measures, all of which are currently marketed or distributed with the claims that these instruments are sensitive and reliable for the early identification of disease or, if untested for this purpose, are promising tools based on other variables. The survey responses for 16 measures/batteries are presented in brief in this review; full survey responses and summary tables are archived and publicly available on the Campaign to Prevent Alzheimer's Disease by 2020 Web site (http://pad2020.org). A decision tree diagram highlighting critical decision points for selecting measures to meet varying clinical trials requirements has also been provided. Ultimately, the survey questionnaire, framework, and decision guidelines provided in this review should remain as useful aids for the evaluation of any new or updated sets of instruments in the years to come.

AB - The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer's disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective therapies. To meet these changing clinical requirements, cognitive measures or tailored batteries of tests must be validated and determined to be fit-for-use for the discrimination between cognitively healthy individuals and persons who are experiencing very subtle cognitive changes that likely signal the emergence of early mild cognitive impairment. We sought to collect and review data systematically from a wide variety of (mostly computer-administered) cognitive measures, all of which are currently marketed or distributed with the claims that these instruments are sensitive and reliable for the early identification of disease or, if untested for this purpose, are promising tools based on other variables. The survey responses for 16 measures/batteries are presented in brief in this review; full survey responses and summary tables are archived and publicly available on the Campaign to Prevent Alzheimer's Disease by 2020 Web site (http://pad2020.org). A decision tree diagram highlighting critical decision points for selecting measures to meet varying clinical trials requirements has also been provided. Ultimately, the survey questionnaire, framework, and decision guidelines provided in this review should remain as useful aids for the evaluation of any new or updated sets of instruments in the years to come.

KW - Alzheimer's disease

KW - Clinical trials

KW - Cognition

KW - Mild cognitive impairment

KW - Neuropsychological assessment

UR - http://www.scopus.com/inward/record.url?scp=79956070940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956070940&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2011.03.009

DO - 10.1016/j.jalz.2011.03.009

M3 - Article

C2 - 21575877

AN - SCOPUS:79956070940

VL - 7

SP - 338

EP - 355

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -